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Background: Millions of older adults who develop community-acquired pneumonia (CAP) 
each year survive, but there is a large knowledge gap on the burden of CAP and the recovery 
process in survivors from the patient perspective.
Methods: The newly developed CAP Burden of Illness Questionnaire was administered through 
a Web survey to a nationwide sample of US adults aged $50 years who were recently diagnosed 
with CAP. Survey respondents with unresolved symptoms or other CAP-related health problems 
completed a second survey 30 days later; a third survey was completed another 30 days later by 
respondents with unresolved symptoms or problems. Nationally representative results describ-
ing the average time to recovery of symptoms and other CAP-related problems were achieved 
using post-stratification weights.
Results: Five hundred participants completed the initial survey. The time to resolution for the 
CAP symptoms of weakness, shortness of breath, and tiredness exceeded 3 weeks on average. 
There was an average of 13 days of absenteeism, and 3 weeks (mean =21 days) before achieving 
full work/activity productivity after CAP. For participants with health conditions that worsened 
from pneumonia, chronic emphysema and chronic obstructive pulmonary disease took the 
longest to return to baseline (mean =60 and 52.4 days, respectively).
Conclusion: The results from this study demonstrate that older adults surviving a CAP episode 
experience a significant multi-symptom illness with long recovery periods to achieve pre-CAP 
health and productivity. These findings highlight the need for further research on effective 
clinician–patient communication, the need for patient-centered outcomes in clinical trials for 
CAP therapeutics, adequate home care during the recovery process, and the pursuit of CAP 
prevention strategies.
Keywords: burden of illness, community-acquired pneumonia, symptoms, patient-reported 
outcomes, longitudinal study, health-related quality of life
Introduction
Approximately, 950,000 cases of community-acquired pneumonia (CAP) occur in the 
USA each year in adults ,65 years of age;1 concurrently, another 1.3 million cases 
occur in older adults $65 years of age.2 CAP is defined as pneumonia contracted in the 
community rather than in a hospital or nursing home setting, or while on a ventilator.3 
With the incidence and severity of CAP increasing notably with age,4 pneumonia 
remains the leading cause of infectious disease mortality in the USA.5 These data 





indicate that millions of older adults in the USA survive 
this disease each year, leaving a large knowledge gap on the 
burden of CAP and the recovery process in survivors from 
the patient perspective.
Prior studies evaluating the time to resolution of CAP 
symptoms have focused on a very limited number of indicators 
selected and worded by physicians.6,7 While returning to work 
or other usual activities are important milestones in the recov-
ery from CAP,8–10 diminished productivity during the CAP 
recovery process may extend beyond absenteeism. There is a 
need to better understand the broad range of problems associ-
ated with CAP recovery based on the patients’ experiences that 
are not measured in generic health status instruments.11,12
Therefore, the CAP Burden of Illness Questionnaire 
(CAP-BIQ) was developed and refined through in-depth 
concept elicitation and cognitive debriefing interviews with 
adults $50 years of age who had recently been diagnosed 
with CAP.13 This report provides results across three suc-
cessive monthly survey administrations up to 180 days after 
CAP diagnosis, detailing the length of time that older adults 
in the USA have CAP symptoms as well as CAP’s detrimental 
effects on other health conditions and productivity.
Methods
study design, participants, and outcome 
measures
The CAP-BIQ was designed using the methodology recom-
mended by the US Food and Drug Administration14 for the 
development of patient-reported outcome measures. Details 
on the development and testing of this survey instrument are 
available elsewhere.13 The questionnaire was administered in 
three waves, each 30 days after the preceding wave (Wave 1, 
Wave 2, and Wave 3), to measure the time course of CAP 
symptoms until resolution. Participants with unresolved CAP 
symptoms or related CAP problems noted at Wave 1 were 
followed 30 days later (Wave 2); those with any unresolved 
CAP symptoms or problems at Wave 2 were followed for 
an additional 30 days (Wave 3). The full CAP-BIQ is avail-
able on the Journal’s website at http://www.dovepress.com/
get_supplementary_file.php?f=85779.pdf. 
Participants were recruited through an e-mail invitation 
from the YouGov® panel of US adults age $50 years. For 
inclusion, participants were required to: have been told by 
a doctor or nurse that they had pneumonia within the past 
120 days; self-report having a chest X-ray or computed 
tomography (CT) scan around the time they were informed 
of their diagnosis; be able to read English; and be willing 
to provide informed consent. To refine CAP identification, 
participants were excluded if they had been admitted to the 
hospital for any reason during the 2 weeks prior to their 
diagnosis or if they resided in a nursing home or assisted care 
facility. Enrollment was closed after the 500th participant 
completed the Wave 1 assessment; a sample size of 500 was 
chosen to give adequate precision on descriptive statistics. 
This study was conducted in accordance with the amended 
Declaration of Helsinki. An independent ethics and review 
committee (Ethical and Independent Review Services, Inde-
pendence, MO, USA) approved the protocol, and written 
informed consent was obtained from all the participants.
statistical analyses
Sample weighting was used to construct a nationally rep-
resentative sample of the US adults aged $50 years. The 
post-stratification weights were calculated using matching 
variables for age, race/ethnicity, and education. Student’s 
t-tests were used to compare mean values, and chi-square 
tests for categorical data inferences. For time to resolution 
of CAP-related symptoms or other issues, the mean, median, 
and interquartile ranges, as well as P-values for the mean 
inferential comparisons were reported. As exploratory analy-
ses, results were stratified to compare by: age group (50–64 
and $65 years old), hospitalization status (yes/no), and risk 
group assignment for developing pneumonia (high risk: 
the presence of asthma, COPD, chronic bronchitis, chronic 
emphysema, heart disease, diabetes, or other immunocom-
promised conditions; low risk: none of the high-risk comorbid 
conditions).15,16 Productivity and caregiver assistance results 
were stratified based on self-reported employment status. All 
the group comparison analyses incorporated a Bonferroni 
correction to alpha to address multiplicity. The analyses were 
performed in SAS version 9.1.3.
Results
The sociodemographic characteristics for all participants 
in the Wave 1 (baseline) survey using the weighted sample 
are fully described elsewhere.13 Briefly summarizing those 
results, 45% were male, the average age was 62.4 years old, 
the majority of participants reported living with a partner 
(79.5%), and 89.2% selected White as their race. The mean 
number of days between CAP diagnosis and Wave 1 CAP-
BIQ completion was 56.9 days. The mean hospital stay due 
to pneumonia was 6.8 days, and 91.4% of these patients were 
hospitalized on the day of diagnosis. The hospitalized group 
was older and had a greater percentage of participants with 
COPD, chronic emphysema, heart disease, and diabetes than 
the nonhospitalized group (P,0.001). High-risk participants 
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were more likely to have high blood pressure, and more than 
twice as likely to be hospitalized compared to the low-risk 
group (P,0.001).13
symptom resolution
Length of time until symptom resolution for all participants 
who experienced at least 1 day with a symptom is reported 
in Table 1. The mean and median duration for fever (feeling 
warm), chills, and sweats was less than a week, whereas the 
mean time for tiredness, weakness, and shortness of breath 
were at least 3 weeks. The other ten symptoms measured in 
this study persisted generally for approximately 1–2 weeks. 
The interquartile ranges for cough, body aches, wheezing, 
and trouble sleeping show that, for at least a quarter of the 
sample, it took nearly 3 weeks to achieve symptom resolu-
tion (Table 1).
Only fever/warmth and chills differed significantly 
(P#0.001) between the age groups, with the younger group 
experiencing the symptoms on average approximately 1–3 
days longer compared to the older group. Low- and high-
risk groups had significant differences only in the duration 
of chills and sweats, with longer mean times (2–3 days) 
observed for the low-risk group. Fever lasted nearly twice 
as long on average in the nonhospitalized group compared 
to those who were hospitalized, but significant differences in 
mean symptom duration between these two groups indicated 
an overall longer recovery time for the hospitalized group 
for tiredness, body aches, and weakness.
Time to resolution of health  
conditions worsened by pneumonia
For those who experienced a worsening of specific health 
conditions due to pneumonia, the means, medians, and inter-
quartile ranges for number of days to return to baseline are 
reported in Table 2. Patients with chronic emphysema had the 
longest duration to return to baseline (mean/median =60/65 
days) followed by COPD (52/44 days); the 75th percen-
tile levels for both of these groups were nearly 3 months 
(89 days). In the subgroup with COPD, the younger group 
took longer to return to their baseline COPD condition than 
the older age group (P=0.004), as did hospitalized partici-
pants compared to nonhospitalized participants (P=0.025), 
although these differences did not reach statistical signifi-
cance when adjusted for multiplicity (P,0.003).
caP impacts on productivity
CAP impacts on work productivity and the need for addi-
tional help are presented in Table 3. There was a greater 
proportion of nonemployed versus employed participants 
who were hospitalized; however, a greater proportion of 
the employed group missed work (92.5%) compared to the 
proportion of the nonemployed group who missed their 
usual daily activities (74.1%; P,0.001). Those who missed 
days of work or usual daily activities were away on average 
for 13 days. Moreover, the mean time before achieving full 
work/activities productivity took nearly 3 weeks (20.1 days), 
and differed between those who were employed (14.2 days) 
and those who were not (24.3 days; P,0.001). As reported 
in Wyrwich et al (2013), 77.4% of participants reported at 
Wave 1 on the need for help with their care from family or 
friends during their bout with CAP.13 On average, partici-
pants receiving this assistance had help for nearly 2 weeks 
(Table 3).
Discussion
This study evaluated the contemporary experience of the 
disease course of CAP in older adults in the USA by docu-
menting the burden of illness in CAP survivors up to 180 days 
after diagnosis from the patient’s perspective. Use of a newly 
developed, disease-specific measure based on what patients 
themselves described as important13 allowed greater detail on 
the presence, duration, and impact of CAP symptoms.
The key findings demonstrate that CAP patients experi-
ence a wide variety of systemic and respiratory symptoms 
that also impact the course of other comorbid illnesses. The 
results also show that symptoms and impacts of symptoms 
can last for days to months after onset of illness, imposing a 
burden on patients and on their caregivers and/or partners. 
Of the 16 symptoms measured, half took more than 2 weeks, 
on average, to resolve; the time to resolution for weakness, 
shortness of breath, and tiredness exceeded 3 weeks. There 
was also a delay of approximately 3 weeks in achieving full 
productivity at work or usual activities.
The length of time to resolution for most longer-lasting 
symptoms did not differ between participants in the younger 
and older age groups, or between the low- and high-risk 
groups. However, for tiredness, body aches, weakness, and 
trouble sleeping, resolution was nearly 1 week longer for 
those who were hospitalized compared to those who were not 
hospitalized. In contrast, early-resolving symptoms of fever/
warmth, sweats, or chills lasted longer in nonhospitalized or 
younger, and low-risk subgroups compared to their respective 
counterparts. Because CAP is caused by pathogenic organ-
isms infecting the pulmonary parenchyma with resultant 
host inflammatory response,17,18 the relatively long duration 
of some symptoms may reflect prolonged host response that 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3 impact of community-acquired pneumonia on absenteeism, productivity, and help from caregiver by employment status








% hospitalized 40.29% 29.98% 45.19% 0.001a
% who missed work or other usual daily activities 79.99% 92.48% 74.06% ,0.001a
number of days of work or other usual daily activities missed  
due to pneumonia 
 Mean, median [25th and 75th percentile]
12.9, 8 [5–14] 9.8, 7 [4–14] 14.7, 10 [6–15] ,001b
number of days until reached usual performance level in work  
or other usual daily activities 
 Mean, median [25th and 75th percentile]
20.1, 14 [7–21] 14.2, 14 [7–14] 24.3, 14 [7–21] ,0.001b
Percent with family or friends helping with care during pneumonia 77.41% 80.83% 75.79% 0.208a
number of days of family or friends helping with care during pneumonia 
 Mean, median [25th and 75th percentile]
13.7, 7 [2–14] 7.5, 7 [2–7] 16.9, 7 [6–18] ,0.001b
Notes: aP-value for percentage comparison; bP-value for mean comparison.
is persistent even after immunological response and control 
of the causative organisms. The magnitude and duration of 
host response may differ in different types of patients, with 
or without antibiotics.
For participants who reported that CAP worsened their 
comorbid conditions, many of the symptoms of these condi-
tions were affected for more than a month; younger or hos-
pitalized participants with worsened COPD were generally 
affected for more than 2 months. Our results are consistent 
with prior investigations showing that over 35% of adults 
with CAP at low risk of death have unresolved CAP-related 
symptoms 1 month post-diagnosis.7
Our findings are also consistent with other studies show-
ing: 1) older patients who survive CAP on average had similar 
symptoms but different severity or duration of symptoms than 
younger patients because of the former’s diminished ability 
to mount a robust immune response,19,20 2) CAP patients 
with other coexisting health conditions had significantly 
impaired general quality of life compared to CAP patients 
without underlying diseases,21 and 3) a median time to return 
to work of 7 days for outpatients and 14 days for inpatients 
in low-risk CAP patients.8 Although time to return to full 
work/activity productivity has not been assessed in previous 
studies, the 3 weeks needed to return to full productivity even 
after return to work highlights the impact of CAP beyond 
traditional productivity measures.
This study has some important limitations. As in previous 
recovery studies,6,22 this study used retrospective recall of 
symptoms, which can be subject to recall bias.23,24 To recruit 
a sufficient sample of older adults with CAP, a window 
of up to 120 days between diagnosis and Wave 1 survey 
completion was necessary. To address the issue of recall 
bias, prospective studies on the burden of CAP in patients 
who are surveyed soon after diagnosis are needed to assess 
the duration of specific CAP symptoms and functioning. 
Such studies are currently underway based on the work 
in this study.25 The use of self-report for the diagnosis of 
pneumonia is also a limitation, although patients are likely 
to correctly remember a seminal event like the diagnosis of 
this potentially life-threatening illness.26,27 We attempted to 
minimize case identification error by asking patients if they 
had a radiologically confirmed diagnosis – as radiography 
is another event that patients aged $50 years are likely to 
accurately recall.28–30 Other studies have also used self-report 
of pneumonia diagnosis,31–33 one of which showed high con-
cordance (82%) between self-diagnosis and medical chart 
and radiographic confirmation of diagnosis.31 Moreover, if 
there was overdiagnosis of pneumonia in the current study 
because of contamination by patients with bronchitis or 
other self-resolving disease, the results would most likely 
underestimate the burden of symptoms.34 Another potential 
limitation that might bias the study results would be if the 
older adults with CAP in the YouGov® panel are different 
from the US general population for this age group in ways 
that cannot be fully adjusted for with the demographic 
weights that were used. Lastly, our study focused solely on 
CAP survivors and may not reflect the presence of symptoms 
at baseline in CAP patients who did not survive their bout 
with pneumonia. Therefore, there may be survivor bias in the 
comparisons of younger versus older patients and hospital-
ized versus nonhospitalized patients if older, hospitalized 
patients have greater mortality. Regardless, our results are 
accurate in terms of the clinical course of patients who will 
be seen in practice by clinicians, since they represent the 
population of survivors.
In addition, although CAP-BIQ captures data to pro-
vide a comprehensive picture of the course of illness and 
disease impact from the patient’s perspective, this lengthy 
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questionnaire may not be appropriate as an outcome 
measure in clinical trials testing treatment effects of vari-
ous interventions for pneumonia. Nonetheless, the results 
from this patient-reported outcome questionnaire can 
inform the development of a shorter instrument for use 
in clinical trials measuring CAP impact at diagnosis and 
recovery. This work based on CAP-BIQ is the basis for 
ongoing studies to prospectively develop a patient-reported 
outcome for clinical trials in patients with radiographically 
confirmed CAP.25
Despite these limitations, this study offers many key 
insights into patients’ experiences with CAP. A major strength 
of the study is the documentation of the content validity and 
understandability of the survey instrument before its use 
in this study, demonstrating a wide array of symptoms not 
captured in previous studies.13 Moreover, few studies have 
examined the long-term effects of CAP beyond the first 
month after diagnosis. Employing a broad Web panel pro-
vided for nationwide enrollment. The use of a single method 
of administration for the survey also eliminates potential 
bias due to a mixing of methods (eg, Web survey, paper and 
pencil, etc). In addition, knowledge of the participants’ age, 
race/ethnicity, and education aided in the construction of 
post-stratification weights matching the US population aged 
$50 years, and corrected for any demographic skewness in 
the sample.
With this evidence from a patient perspective on the 
range of CAP symptoms, functional limitations, and time 
necessary to fully recover, our results can have an impact on 
clinical practice. Greater understanding of the natural history 
of CAP can aid both patients and clinicians in better manag-
ing episodes beyond the acute phase of the disease. Our data 
show a broader range of symptoms than cough, chest pain, 
and dyspnea, which are usually associated with pneumonia, 
indicating that clinicians should inquire about a broader range 
of symptoms. Symptoms often persist longer than a month, 
which exceeds the time when patients complete antibiotic 
therapy. Therefore, patients should be informed that they may 
continue to experience the residual effects of pneumonia long 
beyond the period of active treatment. Patient knowledge of 
the course of the treated disease allows for realistic expecta-
tions of the recovery trajectory, and may reduce unnecessary 
health care use and inappropriate antibiotic prescribing for 
apparent relapses that actually represent the natural course 
of the illness. A previous study reported greater pneumonia-
related ambulatory care visits6 with greater symptom burden 
during CAP recovery, independent of the pneumonia severity 
or comorbidities.
These results also demonstrate that adequate home care 
for a sufficient period is a key consideration, one that needs 
to be addressed either at the time of diagnosis (outpatient 
recovery) or during hospitalization prior to discharge. 
The seriousness and disability associated with CAP over 
an extended period is evidenced by 77% of the study popu-
lation receiving informal care from family or friends for 
almost 2 weeks. Given that 30-day pneumonia readmission 
rate is tracked as an indicator of quality and coordination of 
care by the Center for Medicare and Medicaid Services,35 
providers should involve caregivers in the post-discharge 
planning and follow-up to reduce ambulatory care-sensitive 
readmissions.
Our results also provide evidence to inform future 
research efforts. Future studies may evaluate whether some 
treatments have greater effects than others in decreasing vari-
ous symptoms associated with CAP. Current studies focus 
solely on resolution of a small number of early-resolving 
symptoms (eg, chest pain, cough, and dyspnea); yet the 
demand for patient-centered outcomes fully reflecting the 
patient’s experience has become a major impetus in health 
care reform.36 Therefore, description of treatment effects on 
the spectrum of important CAP symptoms deserves further 
attention. Our results show a wider range of symptoms in 
pneumonia than are usually captured in clinician-reported 
outcomes in the clinical trials of CAP.
Finally, in addition to the substantial number of CAP 
deaths annually, this documented burden of illness among 
CAP survivors emphasizes the importance of CAP pre-
vention in older adults to avoid the prolonged disability 
associated with this disease. Recommended prevention 
strategies include smoking cessation, annual influenza vac-
cination, pneumococcal vaccine for adults aged $65 years 
and those ,65 years old who have underlying medical 
conditions, and educational support for these vulnerable 
populations.37
Conclusion
This study demonstrated that older adults surviving a CAP 
episode experience a significant multi-symptom illness with 
long recovery period before achieving pre-CAP health and 
productivity. These findings highlight the importance of com-
municating the natural course of the illness to inform patient 
and clinician expectations, the need for further research on 
effective clinician–patient communication, adequate home 
care during the recovery process, better patient-centered 
outcomes in evaluating therapies for CAP, and the pursuit 
of CAP prevention strategies.
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